Senseonics See Few Barriers To Adoption For Their Implantable CGM
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
You may also be interested in...
The two diabetes players announced a new integration between their products.
Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.